FGF-23, vitamin D and calcification: the unholy triad
Open Access
- 19 July 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (10) , 2032-2035
- https://doi.org/10.1093/ndt/gfh991
Abstract
Recent studies have changed the commonly held view that phosphate is mostly needed for normal skeletal growth and development. Extensive research in the last decade has identified numerous other essential dynamic functions for phosphate, ranging from signalling to energy metabolism. Abnormal phosphate homeostasis potentially affects functional activities of almost any organ system. Despite its wide biological importance and significance, the regulation of phosphate homeostasis is not yet clearly understood. Recent studies have identified a number of molecules with phosphaturic activities, including fibroblast growth factor-23 (FGF-23) [1], frizzled-related protein 4 [2] and matrix extracellular phosphoglycoprotein [1,3]. Among these recently identified molecules, so far FGF-23 has been implicated in various human diseases, including autosomal dominant hypophosphatemic rickets (ADHR) [4], oncogenic osteomalacia (OOM) [5], X-linked hypophosphatemia (XLH) [6], chronic renal diseases [7] and familial tumoral calcinosis (FTC) [8].Keywords
This publication has 28 references indexed in Scilit:
- An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemiaHuman Molecular Genetics, 2004
- FGF-23 in patients with end-stage renal disease on hemodialysisKidney International, 2004
- The phosphatonin pathway: New insights in phosphate homeostasisKidney International, 2004
- Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agentJournal of Clinical Investigation, 2003
- FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralizationAmerican Journal of Physiology-Endocrinology and Metabolism, 2003
- Increased Circulatory Level of Biologically Active Full-Length FGF-23 in Patients with Hypophosphatemic Rickets/OsteomalaciaJournal of Clinical Endocrinology & Metabolism, 2002
- Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatoninCurrent Opinion in Nephrology and Hypertension, 2002
- MEPE, the Gene Encoding a Tumor-Secreted Protein in Oncogenic Hypophosphatemic Osteomalacia, Is Expressed in BoneGenomics, 2001
- Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalaciaProceedings of the National Academy of Sciences, 2001
- Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23Nature Genetics, 2000